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event/pump thrombosis (six TIA/CVA, two pump thrombo-
ses). At the time of the thromboembolic event/pump throm-
bosis, significantly higher pump power was seen compared 
with the no-thrombosis group (8.2 ± 3.0 vs. 6.4 ± 1.4 W, 
p = 0.02), as well as a trend towards a lower pulse index 
(4.1 ± 1.5 vs. 5.0 ± 1.0, p = 0.05) and a trend towards higher 
pump flow (5.7 ± 1.0 vs. 4.9 ± 1.9 L m, p = 0.06).
The thrombosis group had a more than fourfold higher 
lactate dehydrogenase (LDH) median 1548 [IQR: 754–
2379] vs. 363 [IQR: 325–443] U/L, p = 0.0001). Bacterial 
(n = 4) or viral (n = 1) infection was present in 5 out of 8 
patients. LDH > 735 U/L predicted thromboembolic events/
pump thrombosis with a positive predictive value of 88 %.
Conclusions In patients with a CF-LVAD (HeartMate II), 
thromboembolic events and/or pump thrombosis are associ-
ated with symptoms and signs of acute haemolysis as mani-
fested by a high LDH, elevated pump power and decreased 
pulse index, especially in the context of an infection.
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Introduction
Left ventricular assist devices (LVADs) have increasingly 
become part of the arsenal in the treatment of end-stage 
heart failure [1–3]. Despite advances in pump technology, 
thromboembolic events and acute pump thrombosis remain 
potentially life-threatening complications [4–6]. The clini-
cal presentation varies from acute malfunction of the pump 
with heart failure, arrhythmias and/or to systemic throm-
boembolic events. The exact prevalence and aetiology of 
pump thrombosis is uncertain [7]. Rates of thromboembolic 
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boembolic events/acute pump thrombosis remain poten-
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tinuous-flow left ventricular assist devices (CF-LVAD). We 
sought to determine early signs of thromboembolic event/
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events, including ischaemic stroke and acute pump throm-
bosis, vary between 1 and 14 % among different studies of 
continuous flow (CF) LVADs with either axial or centrifugal 
flow [6, 8–15].
Recently, Starling et al. reported an increasing rate of 
Thoratec HeartMate II pump thrombosis, which was pre-
ceded by increasing lactate dehydrogenase (LDH), and was 
associated with substantial morbidity and mortality [16]. 
Other reports showed a strong association of haemolysis 
with increased pump power and with partial or complete 
LVAD thrombosis [17, 18]. The current guidelines of the 
International Society for Heart and Lung Transplanta-
tion (ISHLT) advise to follow up haemolysis as a sign of 
thrombosis [7]. Haemolysis in the presence of altered pump 
function should prompt admission for optimisation of anti-
coagulation and antiplatelet management and possible pump 
exchange [4]. However, there is no advice in the guidelines 
about detection of thrombosis. Clinically obvious haemoly-
sis could be seen as dark urine, anaemia, jaundice, and/or as 
elevated LDH. Early detection of a thromboembolic event/
pump thrombosis could help in the proper management of 
these LVAD patients.
As thromboembolic events and pump thrombosis are part 
of the same disease spectrum, we sought to analyse the deter-
minants of thromboembolic events and/or pump thrombosis 
in the cohort of patients with a CF-LVAD implanted at our 
institution.
Methods
Forty consecutive patients implanted with axial type con-
tinuous-flow HeartMate II LVADs (Thoratec Corporation, 
Pleasanton, California) in our institution, a tertiary referral 
centre for end-stage heart failure and heart transplantation, 
between December 2006 and July 2013, were included in 
this study.
Data collection
All data from LVAD recipients were stored electronically in 
the hospital electronic patient records. According to Dutch 
law, informed consent was not required, since study-specific 
actions were not implemented. All data were readily avail-
able in the medical records of the patients and were obtained 
during routine treatment. Subsequently, data were processed 
anonymously. Data were retrospectively analysed for demo-
graphic, clinical and LVAD pump parameters. Clinical 
events such as signs of haemolysis, heart failure or infec-
tions were examined and confirmed independently by two 
cardiologists (SA, KC).
Clinical and laboratory investigation
Clinical data, ECG, laboratory and echocardiography were 
collected every 2–3 months or more frequently according 
to the clinical need. Likewise, LVAD interrogation was 
performed regularly at every outpatient clinic visit by an 
LVAD technician. The last 12-lead ECGs before LVAD 
implantation and at follow-up/events were analysed includ-
ing rhythm, QRS width and QTc interval. Blood samples 
were collected serially to assess parameters of haemolysis, 
kidney and liver function as well as inflammation (Table 1). 
The treating cardiologist made the choice of and changes 
in medications including heart failure and antiarrhythmic 
drugs. Twenty-five of 40 patients (63 %) already had an 
implantable cardioverter defibrillator according to the cur-
rent guidelines [19].
Antithrombotic therapy
According to the ISHLT guidelines, postoperative antico-
agulation started after LVAD implantation and completed 
postoperative haemostasis [7]. On postoperative day 1–2, 
intravenous heparin was started if there was no evidence of 
bleeding. On day 2–5, after removal of the chest tubes, aspi-
rin 80 mg daily and vitamin K antagonists were started with 
a target international normalised ratio (INR) of 2.0–2.5. In 
case of a suspected thromboembolic event/pump thrombo-
sis, intravenous heparin was started along with clopidogrel 
75 mg/day. The target INR was increased to 2.5–3.5 or 
3.0–4.0 in case of asymptomatic (laboratory only) signs of 
haemolysis versus thromboembolic event/pump thrombo-
sis, respectively. In case of acute pump thrombosis, throm-
bolytic therapy (alteplase: bolus 15 mg in 1–2 min, followed 
by 0.75 mg/kg (max. 50 mg) continuous infusion in 90 min, 
and 0.5 mg/kg (max. 35 mg) continuous infusion in the sec-
ond 90 min) was given.
Outcome definitions
Pump thrombosis was defined as signs and symptoms of 
otherwise unexplained heart failure with signs of LVAD 
dysfunction and haemolysis, thromboembolic events as 
cerebrovascular accident (CVA) or transient ischaemic 
attack (TIA), as confirmed by a neurologist. Haemolysis 
was diagnosed according to the ISHLT guidelines and the 
Interagency Registry of Mechanically Assisted Circula-
tory Support (INTERMACS) on analysis of pump throm-
bosis [7, 20]. Laboratory and clinical diagnosis of LVAD 
haemolysis and thrombosis were considered according to 
these ISHLT guidelines and the INTERMACS registry. In 
the ISHLT guidelines, screening for haemolysis is indicated 
in the setting of an unexpected drop in the haemoglobin or 
haematocrit level along with other clinical signs of hae-
136 Neth Heart J (2016) 24:134–142
Total population 
(n = 40)
Thromboembolic event or pump 
thrombosis (n = 8)
No thromboembolic event or 
pump thrombosis (n = 32)
p-value
Demographics
Age at implantation, years 46 [41–57] 56 [48–58] 45 [39–55] 0.12
Male gender 26 (65) 6 (75) 20 (63) 0.69
Weight, kg 71 ± 13 75 ± 12 70 ± 13 0.41
BSA, m2 1.87 ± 0.22 1.92 ± 0.19 1.86 ± 0.22 0.44
BMI, kg/m2 22.5 ± 3.0 23.3 ± 2.9 22.3 ± 3.0 0.44
Aetiology
Non-ischaemic cardiomyopathy 23 (57) 4 (50) 19 (59) 0.70
Ischaemic cardiomyopathy 17 (43) 4 (50) 13 (41) 0.70
Comorbidity
Diabetes mellitus 3 (8) 0 3 (9) 1.0
Hypertension 4 (10) 1 (13) 3 (9) 1.0
Previous cardiac surgery 3 (8) 2 (25) 1 (3) 0.10
Previous PCI 15 (38) 2 (25) 13 (41) 0.69
Previous TIA/CVA 2 (5) 0 2 (6) 1.0
INTERMACS class 2.4 ± 1.0 2.8 ± 1.3 2.3 ± 0.9 0.28
I 10 (25) 2 (25) 8 (25) 1.0
II 9 (23) 1 (12.5) 8 (25) 0.66
III 16 (40) 2 (25) 14 (44) 0.44
IV 5 (13) 3 (38) 2 (6) 0.05
Inotropic support 35 (87.5) 5 (63) 30 (94) 0.05
Extra-corporal circulatory support 9 (23) 2 (25) 7 (22) 1.0
Intra-aortic balloon pump 13 (33) 0 13 (41) 0.04
LVAD parameters at discharge
Pump speed, rpm 9325 ± 516 9375 ± 225 9313 ± 568 0.76
Pump flow, L/m 4.9 ± 1.2 4.8 ± 1.0 5.0 ± 1.2 0.67
Pulse index 4.8 ± 0.9 4.9 ± 0.7 4.8 ± 0.9 0.92
Pump power, Watts 6.0 ± 1.3 6.0 ± 1.0 6.0 ± 1.3 0.94
Electrocardiography
Atrial fibrillation 3 (8) 0 3 (9) 1.0
QRS duration, ms 146 ± 71 160 ± 54 143 ± 75 0.56
QTc, ms 462 ± 49 506 ± 35 451 ± 46 0.003
Echocardiography
Left atrial dimensions, mm 48 ± 12 51 ± 9 47 ± 12 0.51
LV end-diastolic dimension, mm 67 ± 16 63 ± 14 66 ± 17 0.46
LV end-systolic dimension, mm 61 ± 16 63 ± 14 61 ± 17 0.76
Baseline laboratory values
Lactate dehydrogenase, U/L 407 [321–849] 361 [277–455] 433 [333–1101] 0.21
NT-proBNP, pmol/L 1136 ± 1112 800 ± 471 1222 ± 1216 0.35
Total bilirubin, umol/L 24 ± 21 20 ± 14 25 ± 23 0.52
BUN, mmol/L 16 ± 10 23 ± 17 14 ± 7 0.03
Creatinine, umol/L 147 ± 89 143 ± 65 148 ± 95 0.89
CRP mg/L 56 ± 71 44 ± 54 59 ± 75 0.56
ALAT, U/L 314 ± 684 126 ± 227 361 ± 752 0.39
ASAT, U/L 297 ± 636 149 ± 268 334 ± 696 0.47
Albumin, g/L 30 ± 6 29 ± 4 30 ± 7 0.66
Haemoglobin, mmol/L 7.1 ± 1.2 7.5 ± 1.4 7.0 ± 1.1 0.26
Haematocrit l/l 0.35 ± 0.06 0.38 ± 0.08 0.34 ± 0.06 0.19
WBC count, 1000/mm3 10.1 ± 5.4 9.3 ± 2.7 10.3 ± 5.9 0.63
Platelet count, 1000/mm3 207 ± 89 250 ± 97 196 ± 85 0.13
Categorical variables are presented as frequencies and percentages. Continuous variables are presented as mean ± standard deviation or median 
[IQR (interquartile range 25th, 75th percentile)].
IQR interquartile range, BSA body surface area, BMI body mass index, PCI percutaneous coronary intervention, TIA transient ischaemic attack, 
CVA ischaemic cerebrovascular accident, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), LVAD left 
ventricular assist device, rpm revolutions per minute, NT-pro-BNP N-terminal of the prohormone brain natriuretic peptide, BUN blood urea 
nitrogen, CRP C-reactive protein, ALT alanine aminotransferase, AST aspartate aminotransferase, WBC white blood cell.
Table 1 Baseline characteristics of all patients with or without thromboembolic events
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Total population (n = 40) Thromboembolic event or 
pump thrombosis (n = 8)
No thromboembolic event or pump 
thrombosis (n = 32)
p-value
Follow-up, days 336 [182–808] 549 [269–856] 297 [152–806] 0.39
Death 8 (20) 0 (0) 8 (25) 0.17
Heart transplantation 18 (45) 4 (38) 14 (44) 1.0
On-going support 12 (30) 3 (38) 9 (28) 0.68
LVAD explantation 1 (3) 1 (13) 0 (0) 0.20
LVAD parametersa
Pump speed, rpm 9245 ± 364 9200 ± 283 9256 ± 384 0.70
Pump flow, L/m 5.1 ± 1.0 5.7 ± 1.0 4.9 ± 0.9 0.06
Pulse index 4.8 ± 1.2 4.1 ± 1.5 5.0 ± 1.0 0.05
Pump power, Watts 6.8 ± 1.9 8.2 ± 3.0 6.4 ± 1.4 0.02
Clinical haemolysis parameters
Macroscopic hemoglobinuria 7 (18) 4 (50) 3 (9) 0.02
LDH levels > 735 U/L 20 (50) 7 (88) 13 (41) 0.04
Free Hb (> 6 indicates 
haemolysis)
15 ± 34 33 ± 58 10 ± 22 0.31
Infection at the time of TE/PT 15 (38) 5 (63) 10 (31) 0.13
Viral 5 (13) 1 (13) 4 (13) 1.0
Bacterial 10 (25) 4 (50) 6 (19) 0.07
Readmissions
Surgery for driveline fracture 6 (15) 1 (13) 5 (16) 1.0
Re-admission due to HF 8 (20) 2 (25) 6 (19) 0.65
Medications at TE/PT or latest follow-up
Vitamin K antagonist 33 (83) 8 (100) 25 (78) 0.31
Aspirin 30 (75) 7 (88) 23 (72) 0.65
Clopidogrel 4 (10) 2 (25) 2 (6) 0.17
Electrocardiography
Atrial fibrillation 6 (15) 1 (13) 5 (16) 0.82
QRS duration, ms at event 148 ± 47 161 ± 45 145 ± 48 0.40
QTc, ms at event 463 ± 75 535 ± 79 445 ± 63 0.001
Echocardiography
Grade aortic regurgitation 1.0 ± 0.9 1.1 ± 1.0 1.0 ± 0,9 0.66
Grade mitral regurgitation 1.2 ± 1.1 1.3 ± 0.9 1.2 ± 1.2 0.89
LV end-diastolic dimension, mm 57 ± 15 61 ± 14 56 ± 16 0.42
LV end-systolic dimension, mm 50 ± 14 52 ± 13 50 ± 15 0.73
Left atrial dimensions, mm 38 ± 11 38 ± 9 38 ± 11 1.0
Laboratory findings
LDH, U/L 382 [331–591] 1548 [754–2379] 363 [325–443] < 0.0001
NT-proBNP, pmol/L 473 ± 890 915 ± 1551 342 ± 558 0.11
Total bilirubin, umol/L 38 ± 79 24 ± 13 41 ± 88 0.60
BUN, mmol/L 10 ± 7 12 ± 9 10 ± 7 0.56
Creatinine, umol/L 136 ± 166 152 ± 148 132 ± 172 0.77
CRP, mg/L 70 ± 91 84 ± 92 67 ± 91 0.64
ALAT, U/L 82 ± 159 162 ± 226 62 ± 135 0.11
ASAT, U/L 121 ± 203 185 ± 156 106 ± 212 0.33
Albumin, g/L 39 ± 9 40 ± 8 39 ± 10 0.77
INR 2.3 ± 1.1 2.4 ± 0.9 2.3 ± 1.1 0.89
Haemoglobin, mmol/L 6.7 ± 1.8 6.0 ± 1.7 6.9 ± 1.8 0.19
Haematocrit, l/L 0.33 ± 0.09 0.31 ± 0.07 0.34 ± 0.09 0.41
Table 2 Comparison of outcome in patients with and without acute pump thrombosis/thromboembolic events at the time of the event or last 
follow-up
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considered to be a statistical trend. Multivariate analysis 
was not done due to the too low number of events and small 
population.
Results
In our single-centre LVAD cohort of bridge-to-transplant 
patients, we found clinical features and other factors associ-
ated with thromboembolic events and acute pump thrombo-
sis in 8 of the 40 patients. One out of 5 patients on LVAD 
support with HeartMate II developed this catastrophic com-
plication during a median follow-up of approximately 18 
months. Thromboembolic events/pump thrombosis occurred 
at a minimum of 34 days and a maximal of 649 days after 
implantation. Demographic, clinical, laboratory, pump and 
echocardiography characteristics of the thrombosis and no-
thrombosis groups at baseline and at follow-up are listed in 
Table 1 and 2, respectively. The patients were divided into 
two groups with and without a thromboembolic event and/
or pump thrombosis. The baseline data are from the pre-
implant period, the laboratory values from the day before 
the operation. In all patients, the LVAD was implanted as 
a bridge to transplant. However, in three patients LVAD 
support ended in destination therapy (severe CVAs in two 
and malignancy in one). In one patient, the LVAD could 
be explanted due to cardiac recovery. All patients were fol-
lowed for a median of 336 (IQR 182–808) days. No patients 
were lost to follow-up.
At baseline, an intra-aortic balloon pump was used sig-
nificantly more often in the thrombosis group, and this 
group had a higher blood urea nitrogen. Furthermore, the 
thrombosis group showed a trend towards INTERMACS 
class IV (p = 0.05) and less inotropic use (p = 0.05). At the 
last follow-up (July 2013), eight (20 %) patients had one 
or more thromboembolic events or pump thrombosis at 
median follow-up of 549 [269–856] days: TIA in 4 patients, 
ischaemic CVA in 3 patients and acute pump thrombosis in 
2 patients. There was no difference in survival between the 
groups censored for heart transplantation or LVAD explan-
molysis, such as haematuria. Screening for haemolysis with 
serum LDH, plasma free haemoglobin in addition to the 
haemoglobin or haematocrit level is recommended [7]. The 
INTERMACS recently specified a new definition, accepted 
by the US Food and Drug Administration and industry, indi-
cating a lower threshold of biochemical markers of haemol-
ysis. They used a cut-off value of serum free haemoglobin 
> 40 mg/dl in association with clinical signs of haemolysis 
beyond 72 h post-implantation to define haemolysis [7].
Statistical analysis
Categorical variables are presented as frequencies and per-
centages. Continuous variables are presented as mean ± 
standard deviation or median (interquartile range 25th, 75th 
percentile). Continuous variables were compared using 
paired or independent t-test, Mann–Whitney U-test or Wil-
coxon’s test when appropriate. When comparing frequen-
cies, the Chi-square or Fisher’s exact test was used, where 
applicable. Cumulative Kaplan–Meier survival curves were 
constructed for each outcome variable. All tests were two-
tailed and p-values less than 0.05 were considered statisti-
cally significant. All p-values between 0.05 and 0.10 were 
Total population (n = 40) Thromboembolic event or 
pump thrombosis (n = 8)
No thromboembolic event or pump 
thrombosis (n = 32)
p-value
WBC count, 1000/mm3 10 ± 6 10 ± 6 10 ± 6 0.99
Platelet count, 1000/mm3 198 ± 84 237 ± 71 188 ± 84 0.14
Categorical variables are presented as frequencies and percentages. Continuous variables are presented as mean ± standard deviation or median 
[IQR (interquartile range 25th, 75th percentile)].
p value < 0.05 is significant. p value 0.05–0.10 is called tendency.
IQR Interquartile range. LVAD left ventricular assist device, rpm revolutions per minute, LDH lactate dehydrogenase, free Hb free haemoglobin, 
TE thromboembolic event, PT pump thrombosis, HF heart failure, LV left ventricle, NT-pro-BNP N-terminal of the prohormone brain 
natriuretic peptide, BUN blood urea nitrogen, CRP C-reactive protein, ALAT alanine aminotransferase, ASAT aspartate aminotransferase, INR 
international normalised ratio, WBC white blood cell.
aLVAD parameters at event or latest follow-up; Values presented as mean (SD), median (interquartile range), or n (%).
Table 2 (continued)
Fig. 1 Kaplan-Meyer curve for survival during LVAD support for the 
thrombosis group (TE/PT+) and the no-thrombosis group (TE/PT−). 
Patients are censored at heart transplantation and LVAD explantation
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Furthermore, the thrombosis group had more than four-
fold higher lactate dehydrogenase levels (median LDH: 
1548 [IQR: 754–2379] vs. 363 [IQR: 325–443] U/L, 
p < 0.0001). In the thrombosis group, infection was associ-
ated with a more than threefold increase of LDH with or 
without clinical signs of TIA/CVA or pump thrombosis. In 
63 % (vs. 31 % in the no-thrombosis group, p = 0.13) of the 
patients presenting with thromboembolism/pump thrombo-
sis, an infection (bacterial in 4 and viral in 1 of the 8 patients) 
was confirmed. At baseline and at follow-up, there was a 
significantly longer corrected-QT interval in the thrombosis 
group.
The sensitivity and specificity of LDH as a marker of 
haemolysis (cut-off value three times the upper limit of nor-
mal (LDH > 735 U/L) were 88 and 97 %, respectively, with 
the positive and negative predictive value being 88 vs. 97 %, 
respectively.
Discussion
In our single-centre LVAD cohort of bridge-to-transplant 
patients, we studied the clinical features and associated fac-
tation (p = 0.13, Fig. 1). One patient with pump thrombo-
sis was treated with acute pump replacement (Table 3 and 
Fig. 2a) and one patient underwent successful thrombolysis 
(Fig. 2b). Four patients in the no-thrombosis group had a 
non-ischaemic CVA, one due to an air embolism and three 
due to intracerebral bleeding. In these patients, a neurologist 
ruled out an ischaemic stroke by CT scan. At the time of 
the thromboembolic event/pump thrombosis, higher pump 
power was seen in thrombosis group compared with the no-
thrombosis group (8.2 ± 3.0 vs. 6.4 ± 1.4 W, p = 0.02), as well 
as a trend towards a lower pulse index (4.1 ± 1.5 vs. 5.0 ± 1.0 
p = 0.05) and a trend towards higher pump flow (5.7 ± 1.0 vs. 
4.9 ± 1.9 L m p = 0.06) Macroscopic haemoglobinuria was 
seen in 4 of 8 patients of the thrombosis group and 3 of 32 
patients of no-thrombosis group (50 vs. 9 %, p = 0.02). The 
patients in the thrombosis group with macroscopic haemo-
globinuria had concomitant infections; at that time they had 
a therapeutic INR or activated partial thromboplastin time. 
They were all empirically treated with intravenous heparin 
and clopidogrel. None developed a thromboembolic event 
or pump thrombosis. The presence of a thrombus in the 
pump was confirmed at explantation by the thoracic surgeon 
and manufacturer in 4 of the 8 patients.
 Table 3 Detailed overview of the eight patients with thromboembolic events during follow-up
Patient no. 1 2 3 4 5 6 7 8
Age (years) 46 49 57 64 37 59 57 54
Sex M M M M F F M M
Aetiology heart failure CMP CMP IHD IHD CMP IHD CMP IHD
INTERMACS class 4 4 2 3 1 1 3 4
Total support time (days) 1603 614 1057 789 483 182 298 180
Time to event (days) 631 175 649 34 195 71 89 49














Culture None None Staphyl. species 
(CNS)






Treatment at the time of 
event
ASA/OAC ASA/OAC ASA/OAC OACa ASAb/OAC ASA/OAC ASA/OAC ASA/OAC
NT-proBNP (pmol/L) 85 48 339 398 65 233 4539 1611
INR 2.2 2.8 2.4 1.4 2.2 4.0 2.1 2.5
Macroscopic haematuria No No No No Yes Yes Yes Yes
Free-Hb 1 9 8 3 50 1 21 172
Peak LDH (U/L) 422 745 2286 757 2131 965 2658 3532










Success of treatment Yes Yes Yes Yes Yes Yes Partly No
Outcome HTX HTX LVAD DT HTX Successful-
ly explanted
HTX: death Semi urgent 
HTX
Urgent HTX
CMP cardiomyopathy, IHD ischaemic heart disease, TIA transient ischaemic attack, CVA ischaemic cerebrovascular attack; e.c.i (e causa 
ignota), CNS coagulase-negative staphylococci, ASA aspirin, OAC oral anticoagulation, INR international normalised ratio, Hb haemoglobin, 
LDH lactate dehydrogenase, HTX heart transplantation, LVAD left ventricular assist device, DT destination therapy.
aNo aspirin due to active duodenal ulcer.
bAspirin started late (5 months post LVAD) due the peri-hepatic haematoma.
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tors in patients with thromboembolic events and acute pump 
thrombosis. One out of 5 patients on LVAD support with 
a HeartMate II developed a thromboembolic event/pump 
thrombosis during a median follow-up of approximately 18 
months. Infection was confirmed at the time of the event 
in two-thirds of these patients. Elevated pump power and 
macroscopic haemoglobinuria predicted thromboembolic 
events/pump thrombosis, but LDH more than three times the 
upper level of normal was the best biochemical parameter 
in predicting and guiding the management of LVAD-related 
thromboembolic events and/or acute pump thrombosis, with 
a sensitivity of 88 % and specificity of 97 %.
Thromboembolic events in continuous-flow LVADs
CF-LVADs have been increasingly used in the last decade 
as a bridge to transplantation [21]. Thromboembolic events/
pump thrombosis remain one the most feared common com-
plications in CF-LVAD patients, although bleeding results in 
the most morbidity and mortality [22–23]. The anticoagula-
tion strategy of Whitson et al. [6] has been nuanced because 
it requires a delicate balance of adequate anticoagulation 
to minimise thrombotic complications but not so excessive 
that it will cause bleeding complications (e.g., gastrointes-
tinal or neurological bleeding). What further complicates 
the clinical picture is the inherent haematological effects of 
CF-LVADs [24–25]. In our cohort there were 23/40 cases 
of early post-implantation bleeding, 21 of which resulted in 
early cardiac tamponade. In their analysis in 2008, John et 
al. [12] found a low thromboembolic risk (4.4 %) in Heart-
Mate II patients even with less stringent requirements for 
anticoagulation, which was confirmed by Menon et al. in 
2012 [13]. From 2013, there has been an increase in throm-
boembolic events/pump thrombosis in HeartMate II patients 
to 13.4 %, according to Whitson et al. [6]. In our report, 5 of 
the 40 patients (12.5 %) had a CVA or pump thrombosis, if 
TIAs were excluded due their mild clinical sequelae.
Acute pump thrombosis
Acute pump thrombosis is a life-threatening condition and 
its optimal management requires early intervention. Detec-
tion of the earliest signs of pump thrombosis could lead to 
successful thrombolysis of a soft developing thrombus [26]. 
Uriel et al. examined 177 LVAD patients of whom 19 (11 %) 
developed acute pump thrombosis, whereby all underwent 
pump exchange; the recurrence rate was 1 %. In one-third 
of the patients, inadequate anticoagulation was found due to 
withholding or cessation of anticoagulation [15]. Thrombol-
ysis could also be used with varying effect, as in our cases 
in Fig. 2a, b and c [11, 27]. In our experience, the use of 
clopidogrel on top of aspirin and coumarins in optimising 
anticoagulation seems effective and safe, but the efficacy of 
Fig. 2 a Explanted pump inlet rotor in a 54-year-old male (patient no. 9 
in Table 3) with acute pump thrombosis. Due to acute pump thrombosis, 
the patient had acute left- and right-sided heart failure with signs of severe 
haemolysis and acute renal failure. Macroscopic fresh white and red old 
thrombus is shown on the rotor, as confirmed by the manufacturer. b LDH 
course of the 57-year-old male (patient no. 7 in Table 3) presenting with 
acute pump thrombosis successfully treated with recombinant tissue-plas-
minogen activator (rt-PA). This patient had several episodes of an abrupt 
peak of LDH during therapeutic INRs associated with relapsing urinary 
tract infections (Citrobacter freundii). At the highest LDH peak he devel-
oped acute pump thrombosis, which was treated with thrombolytic therapy 
(alteplase). Dashed line = upper limit of normal value LDH. c Time course 
of serum LDH (U/L) in a 37-year-old woman (patient no. 5 in Table 3), 
6 months on LVAD support, admitted with a ischaemic cerebrovascular 
event and response to various therapeutic interventions. CVA cerebrovas-
cular accident, INR international normalised ratio, ASA acetylsalicylic 
acid, iv intravenous. Dashed line = upper limit of normal value LDH
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toms and signs of acute haemolysis as manifested by high 
LDH, elevated pump power and decreased pulse index, 
especially in the context of an infection. These symptoms 
and signs could help in the early diagnosis and timely inten-
sification of antithrombotic and/or antiplatelet therapy to 
prevent acute pump thrombosis and thromboembolic events 
or the need for pump replacement.
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